Top Chemicals - Speciality Stocks India (Week of May 10, 2026)

Sector Pulse

The Speciality Chemicals sector, as represented by Anlon Healthcare (AHCL), is witnessing a period of rapid scale-up and operational turnaround. AHCL reported a 281.4% YoY revenue jump to ₹35.78 Cr in Q3 FY26, driven by higher API and intermediate volumes. While sequential revenue declined by 31.6% due to seasonal holiday shutdowns at overseas customer sites, the underlying demand remains high. The company successfully transitioned from a loss in the previous year's corresponding quarter to a PAT of ₹5.15 Cr, supported by an EBITDA margin of 35.06%.

Catalysts Playing Out Across the Pack

The primary catalyst is the inflection of operating leverage, with AHCL reporting capacity utilization exceeding 90%. This has led to a fully booked order book for FY27, totaling over ₹300 Cr across its existing operations and the newly consolidated Apiqo Organics. Furthermore, a geographical expansion strategy is underway, with management targeting a 60% export revenue share in FY27, up from 30% in FY26. This shift is expected to capture a 15-17% margin differential in regulated markets like Brazil and Europe.

What Managements Are Guiding

Management has raised its FY26 revenue guidance to ₹190-200 Cr, up from the previous ₹170-180 Cr. Looking further ahead, the FY27 revenue target is set at ₹370-380 Cr, representing nearly 100% growth. To support this, a greenfield capex of ₹100-120 Cr is planned. EBITDA margins for the consolidated entity are guided to remain in the 30-33% range for FY27.

Sub-Sector Aggregates

Aggregate metrics reveal a sector operating at peak capacity (90%+ utilization) with high visibility on future earnings. The order book for the next fiscal year (₹305-320 Cr) already covers the majority of the guided revenue, suggesting a high degree of predictability. The planned capex of ₹100-120 Cr indicates a high reinvestment rate to capture ongoing demand.

Shared Risks (9-type taxonomy)

Regulatory risks remain a key concern, particularly regarding physical audits by international authorities. AHCL noted that a mandatory four-month shutdown in FY24 for an Anvisa audit significantly impacted past results. Additionally, the pivot toward a 60% export mix increases exposure to FX (currency) fluctuations, a risk that will require active management as the company scales its international footprint.

Bottom Line

The outlook for the sub-sector is positive, characterized by supply-side constraints and high demand visibility. The combination of peak utilization and a fully booked FY27 order book provides a clear path for growth, provided the company successfully executes its greenfield expansion and navigates the regulatory audit landscape.